Federal Register / Vol. 86, No. 8 / Wednesday, January 13, 2021 / Notices 2673 

app stores. Game developers relied on 

Tapjoy to generate revenue for 

themselves and offer gamers a way to 

earn currency to enhance their play. 

However, Tapjoy’s failure to screen 

fraudulent offers left both gamers and 

developers holding the bag. 

The settlement proposed today should 

help reverse the lax policing practices 

that led hundreds of thousands of 

gamers to file complaints. But when it 

comes to addressing the deeper 

structural problems in this marketplace 

that threaten both gamers and 

developers, the Commission will need 

to use all of its tools—competition, 

consumer protection, and data 

protection—to combat middlemen 

mischief, including by the largest 

gaming gatekeepers. 

[FR Doc. 2021–00568 Filed 1–12–21; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF DEFENSE 

GENERAL SERVICES 

ADMINISTRATION 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[OMB Control No. 9000–0200; Docket No. 

2020–0053; Sequence No. 19] 

Submission for OMB Review; 

Protecting Life in Global Health 

Assistance 

Correction 

In notice document 2020–28152 

appearing on pages 83086–83087 in the 

issue of Monday, December 21, 2020, 

make the following correction: 

On page 83087, in the first column, in 

the DATES section, change ‘‘January 20, 

2021’’ to read ‘‘January 21, 2021.’’ 

[FR Doc. C1–2020–28152 Filed 1–12–21; 8:45 am] 

BILLING CODE 1301–00–D 

GENERAL SERVICES 

ADMINISTRATION 

[Notice-MG–2021–01; Docket No. 2021– 

0002; Sequence No. 1] 

Office of Federal High-Performance 

Buildings; Green Building Advisory 

Committee; Notification of Upcoming 

Web Meeting 

AGENCY: Office of Government-Wide 

Policy, General Services Administration 

(GSA). 

ACTION: Meeting notice. 

SUMMARY: In accordance with the 

requirements of the Federal Advisory 

Committee Act, this notice provides the 

agenda for the January 28, 2021 Web 

meeting of the Green Building Advisory 

Committee (the Committee). Interested 

individuals must register to attend as 

instructed below under Supplementary 

Information. 

DATES: The Committee’s Web meeting 

will be held on Thursday, January 28, 

2021, from 11:00 a.m. to 4:30 p.m. 

Eastern time (ET). 

FOR FURTHER INFORMATION CONTACT: Dr. 

Ken Sandler, Designated Federal 

Officer, Office of Federal HighPerformance Buildings, Office of 

Government-wide Policy, General 

Services Administration, 1800 F Street 

NW, (Mail-code: MG), Washington, DC 

20405, at ken.sandler@gsa.gov or 202– 

219–1121. Additional information about 

the Committee, including meeting 

materials and agendas, will be available 

on-line at http://www.gsa.gov/gbac. 

SUPPLEMENTARY INFORMATION: 

Procedures for Attendance and Public 

Comment 

Contact Dr. Ken Sandler at 

ken.sandler@gsa.gov or 202–219–1121 

to register to attend the Committee 

meeting. To attend, submit your full 

name, organization, email address, and 

phone number. Requests to attend the 

meeting must be received by 5:00 p.m. 

ET, on Monday, January 25, 2021. (GSA 

will be unable to provide technical 

assistance to any listener experiencing 

technical difficulties. Testing access to 

the Web meeting site before the calls is 

recommended.) 

Contact Dr. Sandler to register to 

comment during the meeting public 

comment period. Registered speakers/ 

organizations will be allowed a 

maximum of five minutes each and will 

need to provide written copies of their 

presentations. Requests to comment at 

the meeting must be received by 5:00 

p.m., ET, on Monday, January 25, 2021. 

Background 

The Administrator of GSA established 

the Committee on June 20, 2011 

(Federal Register/Vol. 76, No. 118) 

pursuant to Section 494 of the Energy 

Independence and Security Act of 2007 

(EISA, 42 U.S.C. 17123). Under this 

authority, the Committee provides 

independent policy advice and 

recommendations to GSA to advance 

federal building innovations in 

planning, design, and operations to 

reduce costs, enable agency missions, 

enhance human health and 

performance, and minimize 

environmental impacts. 

January 28, 2021 Meeting Agenda 

• Updates and introductions 

• Embodied energy task group findings 

& recommendations 

• Election for Committee Chair 

• Sustainable response to COVID–19 

task group findings & 

recommendations 

• Energy storage task group findings & 

recommendations 

• New committee directions & topics to 

explore 

• Public comment 

• Next steps and closing comments 

Kevin Kampschroer, 

Federal Director, Office of Federal HighPerformance Buildings, General Services 

Administration. 

[FR Doc. 2021–00515 Filed 1–12–21; 8:45 am] 

BILLING CODE 6820–14–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2008–N–0312] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Extralabel Drug 

Use in Animals 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or we) is 

announcing that a proposed collection 

of information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995. 

DATES: Submit written comments 

(including recommendations) on the 

collection of information by February 

12, 2021. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be submitted to https://

www.reginfo.gov/public/do/PRAMain. 

Find this particular information 

collection by selecting ‘‘Currently under 

Review—Open for Public Comments’’ or 

by using the search function. The OMB 

control number for this information 

collection is 0910–0325. Also include 

the FDA docket number found in 

brackets in the heading of this 

document. 

FOR FURTHER INFORMATION CONTACT: 

Domini Bean, Office of Operations, 

Food and Drug Administration, Three 

White Flint North, 10A–12M, 11601 

Landsdown St., North Bethesda, MD 

20852, 301–796–5733, PRAStaff@

fda.hhs.gov. 

2674 Federal Register / Vol. 86, No. 8 / Wednesday, January 13, 2021 / Notices 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 

Extralabel Drug Use for Animals—21 

CFR 530 

OMB Control Number 0910–0325— 

Extension 

The Animal Medicinal Drug Use 

Clarification Act of 1994 (Pub. L. 103– 

396) allows a veterinarian to prescribe 

the extralabel use of approved new 

animal drugs. Also, it permits FDA, if it 

finds that there is a reasonable 

probability that the extralabel use of an 

animal drug may prevent the risk to the 

public health, to establish a safe level 

for a residue from the extralabel use of 

the drug and to require the development 

of an analytical method for the detection 

of residues above that established safe 

level (21 CFR 530.22(b)). Although to 

date, we have not established a safe 

level for a residue from the extralabel 

use of any new animal drug and, 

therefore, have not required the 

development of analytical methodology, 

we believe that there may be instances 

when analytical methodology will be 

required. We are, therefore, estimating 

the reporting burden based on two 

methods being required annually. The 

requirement to establish an analytical 

method may be fulfilled by any 

interested person. We believe that the 

sponsor of the drug will be willing to 

develop the method in most cases. 

Alternatively, FDA, the sponsor, and 

perhaps a third party may cooperatively 

arrange for method development. The 

respondents may be sponsors of new 

animal drugs; State, Federal, and/or 

State Agencies; academia; or 

individuals. 

In the Federal Register of August 6, 

2020 (85 FR 47794), we published a 60- 

day notice requesting public comment 

on the proposed collection of 

information. One comment was received 

but was not responsive to topics 

solicited regarding the information 

collection. 

We estimate the burden of this 

collection of information as follows: 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1

21 CFR part Number of 

respondents 

Number of 

responses per 

respondent 

Total annual 

responses 

Average 

burden per 

response 

Total hours 

530.22(b); Submission(s) of Analytical Method ................... 2 1 2 4,160 8,320 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

Based on a review of the information 

collection since our last request for 

OMB approval, we have made no 

adjustments to our burden estimate. 

Dated: January 5, 2021. 

Lauren K. Roth, 

Acting Principal Associate Commissioner for 

Policy. 

[FR Doc. 2021–00475 Filed 1–12–21; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0161] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Export of Food and 

Drug Administration-Regulated 

Products: Export Certificates 

Correction 

In notice document 2020–28064 

appearing on pages 83091–83092 in the 

issue of Monday, December 21, 2020, 

make the following correction: 

On page 83091, in the second column, 

in the DATES section, change ‘‘January 

20, 2021’’ to read ‘‘January 21, 2021.’’ 

[FR Doc. C1–2020–28064 Filed 1–12–21; 8:45 am] 

BILLING CODE 1301–00–D 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2014–N–0913] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; 513(g) Request for 

Information 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA, Agency, or we) is 

announcing an opportunity for public 

comment on the proposed collection of 

certain information by the Agency. 

Under the Paperwork Reduction Act of 

1995 (PRA), Federal Agencies are 

required to publish notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information and to 

allow 60 days for public comment in 

response to the notice. This notice 

solicits comments on the information 

collection burden estimate for requests 

for a written statement from FDA 

regarding the classification and 

regulatory requirements that may be 

applicable to a particular device (513(g) 

requests). 

DATES: Submit either electronic or 

written comments on the collection of 

information by March 15, 2021. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. Electronic comments must 

be submitted on or before March 15, 

2021. The https://www.regulations.gov 

electronic filing system will accept 

comments until 11:59 p.m. Eastern Time 

at the end of March 15, 2021. Comments 

received by mail/hand delivery/courier 

(for written/paper submissions) will be 

considered timely if they are 

postmarked or the delivery service 

acceptance receipt is on or before that 

date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your